Royal Bank of Canada’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-41
| Closed | – | – | 7455 |
|
|
2018
Q4 | $0 | Sell |
41
-489
| -92% | -$508 | ﹤0.01% | 7586 |
|
|
2018
Q3 | $1K | Sell |
530
-202
| -28% | -$314 | ﹤0.01% | 6669 |
|
|
2018
Q2 | $1K | Buy |
732
+674
| +1,162% | +$1.03K | ﹤0.01% | 6463 |
|
|
2018
Q1 | $0 | Sell |
58
-124
| -68% | -$259 | ﹤0.01% | 7293 |
|
|
2017
Q4 | $0 | Sell |
182
-2,154
| -92% | -$5.45K | ﹤0.01% | 7404 |
|
|
2017
Q3 | $8K | Buy |
2,336
+2,287
| +4,667% | +$7.69K | ﹤0.01% | 6345 |
|
|
2017
Q2 | $0 | Sell |
49
-779
| -94% | -$2.57K | ﹤0.01% | 7143 |
|
|
2017
Q1 | $3K | Sell |
828
-637
| -43% | -$2.48K | ﹤0.01% | 6402 |
|
|
2016
Q4 | $7K | Buy |
1,465
+1,424
| +3,473% | +$5.88K | ﹤0.01% | 6237 |
|
|
2016
Q3 | $0 | Sell |
41
-133
| -76% | -$430 | ﹤0.01% | 6872 |
|
|
2016
Q2 | $0 | Hold |
174
| – | – | ﹤0.01% | 6846 |
|
|
2016
Q1 | $1K | Sell |
174
-42
| -19% | -$163 | ﹤0.01% | 6297 |
|
|
2015
Q4 | $1K | Sell |
216
-855
| -80% | -$3.94K | ﹤0.01% | 6592 |
|
|
2015
Q3 | $4K | Buy |
1,071
+856
| +398% | +$3.93K | ﹤0.01% | 6282 |
|
|
2015
Q2 | $1K | Sell |
215
-57
| -21% | -$547 | ﹤0.01% | 6544 |
|
|
2015
Q1 | $1K | Sell |
272
-291
| -52% | -$1.44K | ﹤0.01% | 6076 |
|
|
2014
Q4 | $2K | Buy |
+563
| New | +$2.27K | ﹤0.01% | 6021 |
|
Royal Bank of Canada's AST Position: Q1 2019 in Review
Royal Bank of Canada sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 41 shares.
Royal Bank of Canada first reported a position in AST in Q4 2014 and held it in 17 quarters. The position peaked at $8K in Q3 2017. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.
- Royal Bank of Canada reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
- Royal Bank of Canada sold 41 Asterias Biotherapeutics Inc. Series A shares in Q1 2019.
- Royal Bank of Canada first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 17 quarters.
- Royal Bank of Canada's Asterias Biotherapeutics Inc. Series A position peaked at $8K in Q3 2017.
- 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.
Based on Royal Bank of Canada's 13F filing for Q1 2019, filed 15 May 2019.